Sionna Therapeutics, Inc. (SION) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Sionna Therapeutics, Inc. (SION) Earnings Overview
As of June 28, 2026, Sionna Therapeutics, Inc. (SION) reported trailing twelve-month net income of -$86M, reflecting -34.3% year-over-year growth. The company earned $-1.90 per diluted share over the past four quarters.
Looking at the long-term picture, SION's historical earnings data spans multiple years. The company achieved its highest annual net income of -$40M in fiscal 2022.
Sionna Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including VRTX ($4.34B net income, 32.7% margin), ABBV ($3.64B net income, 6.9% margin), PTCT (-$187M net income, 39.4% margin), SION has comparable earnings metrics. Compare SION vs VRTX →
SION Earnings vs Peers
Earnings metrics vs comparable public companies
SION Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$75M | -22.0% | -$89M | $-1.88 | - | - |
| 2024 | -$62M | -30.5% | -$71M | $-1.40 | - | - |
| 2023 | -$47M | -17.5% | -$50M | $-1.07 | - | - |
| 2022 | -$40M | - | -$41M | $-0.91 | - | - |
Download Data
Export SION earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SION — Frequently Asked Questions
Quick answers to the most common questions about buying SION stock.
What is SION earnings per share (EPS)?
SION trailing twelve-month (TTM) diluted EPS is $-1.90, reflecting -34.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is Sionna Therapeutics, Inc.'s net income?
Sionna Therapeutics, Inc. (SION) trailing twelve-month net income is $-86M as of 2025. Earnings declined -34.3% year-over-year.
Is SION profitable?
SION is not currently profitable on a TTM basis, reporting a net loss of $-86M. Net margin is N/A. Investors should monitor for a return to profitability.
What is SION's earnings growth rate?
SION compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are SION's profit margins?
Sionna Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -105.2%.
Is SION growing earnings?
SION earnings are declining — EPS fell -34.3% year-over-year. TTM net income dropped to $-86M. This contrasts with the 5-year CAGR of N/A.
What was SION's best earnings year?
Sionna Therapeutics, Inc.'s highest annual net income on record is $-40M, achieved in fiscal year 2022. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were SION's earnings last quarter?
SION's most recent reported quarter was Q1 2026. Net income was $-27M with diluted EPS of $-0.60. For a full breakdown of all quarters, see the quarterly earnings table on this page.